|
SAN DIEGO, CA--(Marketwired - July 01, 2015) - MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ("MabVax" or the "Company"), a clinical stage immuno-oncology drug development company, announced today that it, collectively with OPKO Health, Inc. (NYSE: OPK), approved the release of $3.5 million in funds held in escrow from the $11.7 million financing the Company completed on April 10, 2015. |
